Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Ruth Hyland"'
Publikováno v:
Journal of Proteome Research. 12:4402-4413
Targeted quantitative proteomics using heavy isotope dilution techniques is increasingly being utilized to quantify proteins, including UGT enzymes, in biological matrices. Here we present a multiplexed method using nanoLC-MS/MS and multiple reaction
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57e1295ac857f62a06b57a1851c58eb8
https://doi.org/10.1021/pr4004213
https://doi.org/10.1021/pr4004213
Autor:
Iain Gardner, Jian Lin, Ruth Hyland, Rob Webster, Martin Howard, Tracey Wenham, Tram T. Tran, Richard P. Schneider, Sharan K. Bagal, Jonathan Duckworth, Peter Jones, Kiyoyuki Omoto, David C. Pryde
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 22:2856-2860
Aldehyde oxidase (AO) is a molybdenum-containing enzyme distributed throughout the animal kingdom and capable of metabolising a wide range of aldehydes and N-heterocyclic compounds. Although metabolism by this enzyme in man is recognised to have sign
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e78b8d8734738d21ef393890f3084e23
https://doi.org/10.1016/j.bmcl.2012.02.069
https://doi.org/10.1016/j.bmcl.2012.02.069
Autor:
Karine Bourcier, Nicola Irvine, Russell Jones, Sarah Kempshall, Jacqueline Maximilien, Barry Jones, Ruth Hyland
Publikováno v:
Drug Metabolism and Disposition. 38:923-929
Imidazoles and triazoles represent major classes of antifungal azole derivatives. With respect to UDP-glucuronosyltransferase (UGT) enzymes, the drug metabolism focus has mainly concentrated on their inhibitory effects with little known about azoles
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e0810860c3c31fdf0dc551f01d51e9d4
https://doi.org/10.1124/dmd.109.030676
https://doi.org/10.1124/dmd.109.030676
Autor:
Sarah Kempshall, Angus N. R. Nedderman, Manoli Vourvahis, Claire Collins, Martin Howard, Robert R. LaBadie, Ruth Hyland, Iain Gardner, Michelle Gleave
Publikováno v:
Drug Metabolism and Disposition. 38:789-800
Lersivirine [UK-453,061, 5-((3,5-diethyl-1-(2-hydroxyethyl)(3,5-14C2)-1 H -pyrazol-4-yl)oxy)benzene-1,3-dicarbonitrile] is a next-generation non-nucleoside reverse transcriptase inhibitor, with a unique binding interaction within the reverse transcri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f13ccf75a19c968e0e926bc9fa4766dc
https://doi.org/10.1124/dmd.109.031252
https://doi.org/10.1124/dmd.109.031252
Publikováno v:
Drug Discovery Today. 14:964-972
Owing to the polymorphic nature of CYP2D6, clinically significant issues can arise when drugs rely on that enzyme either for clearance, or metabolism to an active metabolite. Available screening methods to determine if the compound is likely to cause
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f73f8adff6d02f81c2599bcabdf21ef
https://doi.org/10.1016/j.drudis.2009.07.005
https://doi.org/10.1016/j.drudis.2009.07.005
Autor:
Mike West, Michael R. Wester, R. Scott Obach, Chad L. Stoner, Ruth Hyland, Michael Zientek, Kuresh Youdim
Publikováno v:
Hit and Lead Profiling
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c5dbabfbef085c27b8096c241fdb3e09
https://doi.org/10.1002/9783527627448.ch8
https://doi.org/10.1002/9783527627448.ch8
Autor:
Alex Phipps, Jack Cook, Amanda Darekar, Kuresh Youdim, Susan Hurst, Feng Guo, David R. Plowchalk, R. Scott Obach, Odette A. Fahmi, Maurice Dickins, Ruth Hyland
Publikováno v:
Drug Metabolism and Disposition. 37:1658-1666
Cytochrome P450 3A4 (CYP3A4) is the most important enzyme in drug metabolism and because it is the most frequent target for pharmacokinetic drug-drug interactions (DDIs) it is highly desirable to be able to predict CYP3A4-based DDIs from in vitro dat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c40c53d3226d208a5d7d03448252310
https://doi.org/10.1124/dmd.108.026252
https://doi.org/10.1124/dmd.108.026252
Autor:
Douglas Burdette, Howard Miller, D. A. Smith, Lance Heinle, Caroline A. Lee, Mary Beth Dunklee, Archie Thurston, Odette A. Fahmi, Michael Zientek, Ruth Hyland
Publikováno v:
Journal of Pharmacological and Toxicological Methods. 58:206-214
Introduction: Inhibition of cytochrome P450 (CYP) is a principal mechanism for metabolism-based drug–drug interactions (DDIs). This article describes a robust, high-throughput CYP-mediated DDI assay using a cocktail of 5 clinically relevant probe s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66c56666215b3fe919b2afc2cebbaae0
https://doi.org/10.1016/j.vascn.2008.05.131
https://doi.org/10.1016/j.vascn.2008.05.131
Publikováno v:
British Journal of Clinical Pharmacology. 66:498-507
WHAT IS ALREADY KNOWN ABOUT THE SUBJECT • Maraviroc is known to undergo oxidative metabolism in vivo and is a substrate for cytochrome P450 (CYP). • Simcyp™ has recently become more widely used for the prediction of CYP-mediated drug–drug int
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb6a9b92a0e0b26de6068192b8ce5b3d
https://doi.org/10.1111/j.1365-2125.2008.03198.x
https://doi.org/10.1111/j.1365-2125.2008.03198.x
Publikováno v:
Drug Metabolism and Disposition. 34:1516-1522
Minimizing interindividual variability in drug exposure is an important goal for drug discovery. The reliability of the selective CYP2D6 inhibitor quinidine was evaluated in a retrospective analysis using a standardized approach that avoids laborator
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1846e6bfc20f0ab58f2c8d9d369e43ac
https://doi.org/10.1124/dmd.105.008714
https://doi.org/10.1124/dmd.105.008714